HUC-3443 by Huons for Idiopathic (Essential) Hypertension: Likelihood of Approval

HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.

Cautious Return-to-Play Appears Safe for Athletes With Heart Conditions

For elite-level athletes diagnosed with a genetic heart disease, the first available outcomes data on a return-to-play (RTP) protocol favored the approach, comprising shared decision-making

August 15, 2023

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program 19-Apr-2024 / 07:00 CET/CEST Paris (France) and

April 20, 2024

Doctors Sue Google Over Bad Reviews; $425K Stolen From UPMC? Doc’s Alleged Sex Crime

Doctors in Japan have sued Google over bad reviews. (Japan Times) A pharmacy employee at UPMC Presbyterian has been accused of stealing more than $425,000

April 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.